NCT02374372.

Trial name or title	Prospective randomized study comparing the hemodiafiltration on‐line and conventional hemodialysis in terms of cost‐benefit
Methods	Country: Canada Allocation: randomised Endpoint classification: efficacy study Intervention model: parallel assignment Masking: open label Primary purpose: treatment
Participants	Chronic renal failure; haemodialysis
Interventions	Active comparator: conventional haemodialysis Active comparator: haemodiafiltration on‐line haemodiafiltration
Outcomes	Compare the medication cost between the 2 groups (HD and HDF) (time frame: 3 years) Demonstrate lower cost of erythropoietin in HDF, with same control of anaemia to HD group (time frame: 3 years) Demonstrate lower cost of phosphate binder in HDF, with same control of phospho‐calcium balance to HD group (time frame: 3 years) Demonstrate lower need of erythropoietin and best control of anaemia in HDF (time frame: 3 years) Demonstrate lower need of phosphate binder and best control of phospho‐calcium balance in HDF (time frame: 3 years) Demonstrate less hospitalisation stay and cost related in HDF group (time frame: 3 years) Stabilisation or regression of left ventricular hypertrophy (time frame: 3 years)
Starting date	January 2011
Contact information	Renée Lévesque, MD, renee.levesque@sympatico.ca Marie‐Line Caron, B.Sc, marie‐line.caron.chum@ssss.gouv.qc.ca
Notes	Estimated completion date: June 2016 Source: clinicaltrials.gov/ct2/show/study/NCT02374372